• Recruiting

NCT04855929: Phase 1: Safety and Therapeutic Activity of ANV419 in RRMM - ANV419-001

NCT04855929: Phase 1: A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer and Multiple Myeloma. (ANV419-001)

 ANV419 Anaveon

NCT04855929: Phase 1: A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer and Multiple Myeloma. (ANV419-001)


Sponsor

Anaveon AG

 

ClinicalTrials.gov Identifier: NCT04855929

Official Title: ANV419 Single Agent First in Human Study Phase 1: Open-label, Dose Escalation Study in Patients With Relapsed/Refractory Advanced Solid Tumors and Multiple Myeloma

First Posted: April 22, 2021

Click here for details on Clinicaltrials.gov

 

ANV-419

CD122-selective IL-2/Anti-CD25 Antibody-like Fusion Protein ANV419 (Code C180674)

Antibody-like Fusion Protein ANV419

ANV 419

ANV-419

ANV419

CD122-selective IL-2/Anti-CD25 Antibody-like Fusion Protein ANV419

CD122-selective IL-2/Anti-IL-2Ra Antibody Fusion Protein ANV419

 

Drug: ANV419

 

Locations

Europe

Spain

Switzerland

United Kingdom








Posts Archive